| ID | 10060 |
| Vaccine Name | JCOVDEN |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Non-replicating viral vector |
| Vaccine Status | Approved |
| Manufacturer | Janssen Pharmaceutical |
| Year of Manufacturing | 2020 |
| Manufacturing Country | USA |
| Age | 18 years and above |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | US FDA, WHO, Africa Regulatory Taskforce Endorsed, Caribbean Regulatory System Emergency Use Recommendation |
| Collaborating Organisation | NA |
| Other Countries | Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, USA |
| Trade Name | Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine |
| PMID | NA |
| Clinical Trial ID | NCT04436276 |
| Reference Link | https://clinicaltrials.gov/show/NCT04436276 |
| Additional Links | NA
|